Actinium Pharmaceuticals Inc (ATNM)

$1.07 +0.02 (1.90%)
Market Cap 32.76M
Revenue (ttm) 0.00
Net Income (ttm) -38.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 113,100
Avg Vol 142,818
Day's Range N/A - N/A
Shares Out 31.20M
Stochastic %K 29%
Beta -0.30
Analysts Strong Sell
Price Target $5.00

Company Profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Address:
100 Park Avenue, 23rd Floor, New York, United States
Pinto72
Pinto72 Feb. 24 at 10:16 PM
$ATNM ATNMQ 🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣
0 · Reply
dm4
dm4 Feb. 24 at 7:22 PM
$IOVA $ATNM
0 · Reply
dm4
dm4 Feb. 24 at 7:19 PM
$IOVA $ATNM TIL needs lymphodepletion!!! Another huuge market for IOMAB
2 · Reply
gooddoggie
gooddoggie Feb. 24 at 6:31 PM
$ATNM Idea: smart investors are mortgaging their homes to the max so they can buy as much ATNM as possible.
1 · Reply
ppl_first
ppl_first Feb. 24 at 4:52 PM
$ATNM Drag: Development-stage radiopharma risk plus long timeline. Recovery: Only on strong clinical data. Pure binary.
1 · Reply
Pinto72
Pinto72 Feb. 24 at 3:33 PM
$ATNM This won’t even see $2 AS SOON, without a reverse split! 🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣
0 · Reply
Pickerbefore
Pickerbefore Feb. 24 at 2:25 PM
$ATNM Steve O looks like he had the sense to leave Seth with his thumb up his butt. The Company will not do anything until Seth is gone. He is a bad man.
0 · Reply
gooddoggie
gooddoggie Feb. 24 at 11:13 AM
$ATNM The $84.20 expected this year. Will be from the Merck acquisition. “Actinium Pharmaceuticals (ATNM) is conducting clinical trials combining its CD33-targeting radioconjugate, Actimab-A, with Merck’s Keytruda to treat solid tumors. The strategy aims to improve Keytruda's efficacy by using Actimab-A to deplete myeloid-derived suppressor cells (MDSCs), which limit the effectiveness of PD-1 inhibitors in cancers like HNSCC and NSCLC.”c
2 · Reply
johnny4cures
johnny4cures Feb. 24 at 9:16 AM
$ATNM https://www.hhs.gov/press-room/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases.html#:~:text=WASHINGTON%20%E2%80%94%20FEBRUARY%2023%2C%202026%20%E2%80%94,patients%20who%20need%20them%20most.%E2%80%9D
1 · Reply
johnny4cures
johnny4cures Feb. 24 at 2:38 AM
$ATNM
1 · Reply
Latest News on ATNM
BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

Feb 17, 2026, 8:00 AM EST - 7 days ago

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

Dec 12, 2025, 8:45 AM EST - 2 months ago

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Dec 1, 2025, 8:45 AM EST - 3 months ago

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

Nov 17, 2025, 8:30 AM EST - 3 months ago

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

NVS

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 27, 2025, 7:00 AM EDT - 4 months ago

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 24, 2025, 8:30 AM EDT - 4 months ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 12:10 PM EDT - 4 months ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Oct 13, 2025, 8:30 AM EDT - 4 months ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Jul 31, 2025, 8:30 AM EDT - 7 months ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

Jun 23, 2025, 11:30 AM EDT - 8 months ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

May 22, 2025, 5:45 AM EDT - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

May 15, 2025, 1:43 PM EDT - 10 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNM

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

May 14, 2025, 1:26 PM EDT - 10 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

May 6, 2025, 8:45 AM EDT - 10 months ago

Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Apr 30, 2025, 7:25 AM EDT - 10 months ago

Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:30 AM EDT - 10 months ago

Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 10 months ago

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Apr 24, 2025, 5:00 AM EDT - 10 months ago

ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

Apr 19, 2025, 8:20 AM EDT - 11 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Apr 17, 2025, 5:45 AM EDT - 11 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Pharmaceuticals, Inc. Lawsuit - ATNM

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

Apr 16, 2025, 10:01 AM EDT - 11 months ago

Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm

IBTA

Pinto72
Pinto72 Feb. 24 at 10:16 PM
$ATNM ATNMQ 🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣
0 · Reply
dm4
dm4 Feb. 24 at 7:22 PM
$IOVA $ATNM
0 · Reply
dm4
dm4 Feb. 24 at 7:19 PM
$IOVA $ATNM TIL needs lymphodepletion!!! Another huuge market for IOMAB
2 · Reply
gooddoggie
gooddoggie Feb. 24 at 6:31 PM
$ATNM Idea: smart investors are mortgaging their homes to the max so they can buy as much ATNM as possible.
1 · Reply
ppl_first
ppl_first Feb. 24 at 4:52 PM
$ATNM Drag: Development-stage radiopharma risk plus long timeline. Recovery: Only on strong clinical data. Pure binary.
1 · Reply
Pinto72
Pinto72 Feb. 24 at 3:33 PM
$ATNM This won’t even see $2 AS SOON, without a reverse split! 🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!🤣🤣🤣🤣🤣
0 · Reply
Pickerbefore
Pickerbefore Feb. 24 at 2:25 PM
$ATNM Steve O looks like he had the sense to leave Seth with his thumb up his butt. The Company will not do anything until Seth is gone. He is a bad man.
0 · Reply
gooddoggie
gooddoggie Feb. 24 at 11:13 AM
$ATNM The $84.20 expected this year. Will be from the Merck acquisition. “Actinium Pharmaceuticals (ATNM) is conducting clinical trials combining its CD33-targeting radioconjugate, Actimab-A, with Merck’s Keytruda to treat solid tumors. The strategy aims to improve Keytruda's efficacy by using Actimab-A to deplete myeloid-derived suppressor cells (MDSCs), which limit the effectiveness of PD-1 inhibitors in cancers like HNSCC and NSCLC.”c
2 · Reply
johnny4cures
johnny4cures Feb. 24 at 9:16 AM
$ATNM https://www.hhs.gov/press-room/fda-launches-framework-accelerating-development-individualized-therapies-ultra-rare-diseases.html#:~:text=WASHINGTON%20%E2%80%94%20FEBRUARY%2023%2C%202026%20%E2%80%94,patients%20who%20need%20them%20most.%E2%80%9D
1 · Reply
johnny4cures
johnny4cures Feb. 24 at 2:38 AM
$ATNM
1 · Reply
Ferric
Ferric Feb. 23 at 10:57 PM
$ATNM who remembers Vanda, and how they stood their ground against the FDA...when the FDA refused to progress them. It happened approximately around the same time they gave our company a hard time. Granted, for different reasons. But, they had the conviction to fight it. How has it paid off for them? Two approvals since.
3 · Reply
Pinto72
Pinto72 Feb. 23 at 10:49 PM
$ATNM BANKRUPTCY AS SOON!!!!
0 · Reply
mauryrosen
mauryrosen Feb. 23 at 10:30 PM
$ATNM https://www.bloomberg.com/news/articles/2026-02-23/merck-creating-cancer-unit-as-patent-cliff-looms-wsj-says?embedded-checkout=true
2 · Reply
tjm1
tjm1 Feb. 23 at 9:50 PM
$ATNM and yet the board (or lack of board) keeps Seth? I need a therapist.
0 · Reply
Pinto72
Pinto72 Feb. 23 at 5:43 PM
$ATNM Wow! That @johnny4skin is pathetic! Trying to pump this trash with her multiple accounts is quite comical. BANKRUPTCY is inevitable.🚀🚀🚀🚀🚀 eXtReEmLeE bUlLiSh!!!!!🤣🤣🤣🤣🤣
0 · Reply
Jimmy1940
Jimmy1940 Feb. 23 at 4:52 PM
$ATNM from StockScan , Is someone being sarcastic? What's the meaning of this...ha The Actinium Pharmaceuticals Inc (ATNM) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $84.20, representing a +8010.19% increase from the current price of $1.0382. The highest analyst price target is $85.94, and the lowest is $82.46.
4 · Reply
Pickerbefore
Pickerbefore Feb. 23 at 2:08 PM
$ATNM now that Steve O is gone maybe the BOD will get rid of the other rat in charge. He should retire with all the money he got since nobody would want him with his dismal track record.
0 · Reply
johnny4cures
johnny4cures Feb. 23 at 1:56 PM
$ATNM This is for multiple myeloma and shows the hunt is still on for LOE deals. Those 6 month OS look very familiar to SIERRA, dont count it out (partnership)just yet and keep the faith its the nature of the business. https://finance.yahoo.com/news/gilead-sciences-acquire-arcellx-maximize-110100527.html
0 · Reply
johnny4cures
johnny4cures Feb. 23 at 1:00 AM
$ATNM LOE in the 100s of billion dollars up and coming. When is the question not a matter of who. This pipeline is amazing, see go to company information on their pipeline.
0 · Reply
johnny4cures
johnny4cures Feb. 23 at 12:56 AM
$ATNM These clowns posting about the old company short arguments. This is a new ball game, they at the wrong game!
0 · Reply
johnny4cures
johnny4cures Feb. 23 at 12:54 AM
$ATNM We Nuke Cancer And in the top 3 cancers, 1st in class, patents up to 250 now, plus growing and clows still bash. LOE is all you gotta say
0 · Reply
johnny4cures
johnny4cures Feb. 23 at 12:47 AM
$ATNM Bashers thesis is fading, they getting cheap shares, not here, diamond hands. Bet the bashers are part of the old school gig. Sweat shops are doing well but there will come a time when karma arrives.
0 · Reply